The discovery of navitoclax, a Bcl-2 family inhibitor

Topics in Medicinal Chemistry

Volumn 8, Issue , 2012, Pages 231-258

  Wendt, Michael D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Apoptosis; Bcl 2; Bcl 2 family; Bcl xL; Cancer; Oral bioavailability; Structure based drug design

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CYTOTOXIC AGENT; ETOPOSIDE; NAVITOCLAX; PROTEIN BAD; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL 2 INHIBITOR; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN BCL XL INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; FOLLICULAR LYMPHOMA; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHOBICITY; LUNG SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

EID: 84864063343     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/978-3-642-28965-1_7     Document Type: Article

References (89)

1. Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:205-219
2. Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462
3. Reed JC (2000) Mechanisms of apoptosis. Am J Pathol 157:1415-1430
4. Strasser A, Huang DC, Vaux DL (1997) The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumorigenesis and resistance to chemotherapy. Biochim Biophys Acta 1333:F151-F178
5. Guchelaar HJ, Vermes A, Vermes I, Haanen C (1997) Apoptosis - molecular mechanisms and implications for cancer-chemotherapy. Pharm World Sci 19:119-125
6. Reed JC (1995) Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett 82 (83):155-158
7. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47-59
8. Green DR, Evan GI (2002) A matter of life and death. Cancer Cell 1:19-30
9. van Delft MF, Huang DC (2006) How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 16:203-213
10. Huang DCS, Strasser A (2000) BH3-only proteins - essential initiators of apoptotic cell death. Cell 103:839-842
11. Chittenden T (2002) BH3 domains: intracellular death-ligands critical for initiating apoptosis. Cancer Cell 2:165-166
12. Walensky LD, Gavathiotis E (2011) BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci 36:642-652
13. Dewson G, Kluck RM (2009) Mechanisms by which Bak and Bax permeabilize mitochondria during apoptosis. J Cell Sci 122:2801-2808
14. Certo M, Del Gaizo MV, Nishino M et al (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351-365
15. Amundson SA, Myers TG, Scudiero D et al (2000) An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 60:6101-6110
16. Sattler M, Liang H, Nettesheim D et al (1997) Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275:983-986
17. Petros AM, Nettesheim DG, Wang Y et al (2000) Rationale for Bcl-x(L)/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 9:2528-2534
18. Zhang H, Nimmer P, Rosenberg SA et al (2002) Development of a high-throughput fluorescence polarization assay for Bcl-xL. Anal Biochem 307:70-75
19. Petros AM, Medek A, Nettesheim DG et al (2001) Solution structure of the antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA 98:3012-3017
20. Aouacheria A, Brunet F, Gouy M (2005) Phylogenomics of life-or-death switches in multicellular animals: Bcl-2, BH3-only, and BNip families of apoptotic regulators. Mol Biol Evol 22:2395-2416
21. Day CL, Chen L, Richardson SJ et al (2005) Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem 280:4738-4744
22. Muchmore SW, Sattler M, Liang H et al (1996) X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381:335-341
23. Denisov AY, Madiraju MSR, Chen G et al (2003) Solution structure of human BCL-w: modulation of ligand binding by the C-terminal helix. J Biol Chem 278:21124-21128
24. Wendt MD (2008) Discovery of ABT-263, a Bcl-family protein inhibitor. Observations on targeting a large protein-protein interaction. Expert Opin Drug Discov 3:1123-1143
25. Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein-protein interactions; progressing towards the dream. Nat Rev Drug Discov 3:301-317
26. Chène P (2006) Drugs targeting protein-protein interactions. ChemMedChem 1:400-411
27. Coyne AG, Scott DE, Abell C (2010) Drugging challenging targets using fragment-based approaches. Curr Opin Chem Biol 14:299-307
28. Congreve M, Chessari G, Tisi D, Woodhead AJ (2008) Recent developments in fragmentbased drug discovery. J Med Chem 51:3661-3680
29. Cuningham BC, Wells JA (1989) High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244:1081-1085
30. Clackson T, Wells JA (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267:383-386
31. Clackson T, Ultsch MH, Wells JA, de Vos AM (1998) Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol 277:1111-1128
32. Hajduk PJ (2006) Applications of receptor-based NMR screening in drug discovery. Mod Magn Reson 2:1383-1389
33. Petros AM, Dinges J, Augeri DA et al (2006) Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 49:656-663
34. Oltersdorf T, Elmore SW, Shoemaker AR et al (2005) An inhibitor of Bcl family proteins induces regression of solid tumours. Nature 435:677-681
35. Wendt MD, Shen W, Kunzer A et al (2006) Discovery and structure-activity relationships of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem 49:1165-1181
36. Mao H, Hajduk PJ, Craig R et al (2001) Rational design of diflunisal analogous with reduced affinity for human serum albumin. J Am Chem Soc 123:10429-10435
37. Curry S, Mandelkow H, Brick P, Franks N (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 5:827-835
38. Hajduk PJ, Mendoza R, Petros AM et al (2003) Ligand binding to domain-3 of human serum albumin: a chemometric analysis. J Comput-Aided Mol Des 17:93-102
39. Shoemaker AR, Oleksijew A, Bauch J et al (2006) A small-molecule inhibitor of Bcl-xL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 66:8731-8739
40. Tsujimoto Y, Finger LR, Yunis J et al (1984) Cloning of the chromosomal breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097-1099
41. Petros AM, Olejniczak ET, Fesik SW (2004) Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644:83-94
42. Wendt MD (2012) Targeting protein-protein interactions: dual inhibitors of Bcl-2 and Bcl-xL. In: Morphy JR, Harris CJ (eds) Designing multi-target drugs. RSC, Cambridge
43. Bruncko M, Oost TK, Belli BA et al (2007) Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem 50:641-662
44. Goh CS, Milburn D, Gerstein M (2004) Conformational changes associated with proteinprotein interactions. Curr Opin Struct Biol 14:104-109
45. Lee EF, Czabotar PE, Smith BJ et al (2007) Crystal structure of ABT-737 complexed with BclxL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14:1711-1713
46. Porter J, Payne A, de Candole B et al (2009) Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors. Bioorg Med Chem Lett 19:230-233
47. Castro AC, Grogan MJ, Holson EB et al US Patent App Publ 2007/0155705 A1, Jul 5 2007
48. Petros AM, Huth JR, Oost T et al (2010) Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett 20:6587-6591
49. Del Gaizo MV, Brown JR, Certo Met al (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117:112-121
50. Vogler M, Dinsdale D, Sun S-M et al (2008) A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 15:820-830
51. Trudel S, Stewart AK, Li Z et al (2007) The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 13:621-629
52. Chauhan D, Velankar M, Brahmandam M et al (2007) A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26:2374-2380
53. Kline MP, Rajkumar SV, Timm MM et al (2007) ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 21:1549-1560
54. Kohl TM, Hellinger C, Ahmed F et al (2007) BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 21:1763-1772
55. Konopleva M, Contractor R, Tsao T et al (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388
56. Kuroda J, Puthalakath H, Cragg MS et al (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103:14907-14912
57. Del Gaizo MV, Schlis KD, Sallan SE et al (2008) BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111:2300-2309
58. Tahir SK, Yang X, Anderson MG et al (2007) Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 67:1176-1183
59. Kaiser U, Schilli M, Haag U et al (1996) Expression of Bcl-2 protein in small cell lung cancer. Lung Cancer 15:31-40
60. Sartorius UA, Krammer PH (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97:584-592
61. Zhang YK, Fujita N, Tsuruo T (1999) p21(waf1/cip1) acts in synergy with Bcl-2 to confer multidrug resistance in a comptothecin-selected human lung-cancer cell line. Int J Cancer 83:790-797
62. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA (1998) Synergistic toxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78:1035-1042
63. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R (1996) Bcl-2 oncoprotein expression is increased especially in the portions of small cell carcinoma within the combined type of small cell lung cancer. Tumour Biol 17:341-344
64. Hann CL, Daniel VC, Sugar EA et al (2008) Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 68:2321-2328
65. Cragg MS, Harris C, Strasser A, Scott CL (2009) Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 9:321-326
66. Paoluzzi L, Gonen M, Bhagat G et al (2008) The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112:2906-2916
67. Lieber J, Eicher C, Wenz J et al (2011) The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. BMC Cancer 11:362
68. Deng J, Carlson N, Takeyama K et al (2007) BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12:171-185
69. Huang S, Sinicrope FA (2008) BH3 Mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 68:2944-2951
70. Chen S, Dai Y, Pei XY, Grant S (2009) Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 29:6149-6169
71. Chen S, Dai Y, Harada H et al (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67:782-791
72. van Delft MF, Wei AH, Mason KD et al (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399
73. Park C-M, Bruncko M, Adickes J et al (2008) Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 51:6902-6915
74. Tse C, Shoemaker AR, Adickes J et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421-3428
75. Shoemaker AR, Mitten MJ, Adickes J et al (2008) Activity of the Bcl-2 family inhibitor ABT- 263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14:3268-3277
76. Ackler S, Mitten MJ, Foster K et al (2010) The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmocol 66:869-880
77. Ackler S, Xiao Y, Mitten MJ et al (2008) ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 7:3265-3274
78. Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Ann Rev Pharmacol Toxicol 49:223-241
79. Kazi A, Sun J, Doi K et al (2011) The BH3 a-helical mimic BH3-M6 disrupts Bcl-XL, Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. J Biol Chem 286:9832-9842
80. Pitter K, Bernal F, Labelle J, Walensky LD (2008) Dissection of the BCL-2 family signaling network with stabilized alpha-helices of BCL-2 domains. Methods Enzymol 446:387-408
81. Hajduk P (2006) Fragment-based drug design: how big is too big? J Med Chem 49:6972-6976
82. Eyrisch S, Helms V (2007) Transient pockets on protein surfaces involved in protein-protein interactions. J Med Chem 50:3457-3464
83. Palm K, Luthman K, Ungell A-L, Strandlund G, Artursson P (1996) Correlation of drug absorption with molecular surface properties. J Pharm Sci 85:32-39
84. Palm K, Stenberg P, Luthman K, Artursson P (1997) Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 14:568-571
85. Egan WJ, Lauri G (2002) Prediction of intestinal permeability. Adv Drug Deliv Rev 54:273-289
86. Martin Y (2005) A bioavailability score. J Med Chem 48:3164-3167
87. Dobson PD, Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7:205-220
88. Koepsell H, Endou H (2004) The SLC22 drug transporter family. Pflugers Arch 447:666-676
89. Hagenbuch B, Meier PJ (2004) Organic anion transporting polypetptides of the OATP/LSC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665